The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report

Journal of the American Medical Association

Volumn 289, Issue 19, 2003, Pages 2560-2572

  Chobanian, Aram V ^a   Bakris, George L ^b   Black, Henry R ^b   Cushman, William C ^c   Green, Lee A ^d   Izzo, Joseph L ^e   Jones, Daniel W ^f   Materson, Barry J ^g   Oparil, Suzanne ^h   Wright, Jackson T ^i,ar   Roccella, Edward J ^j   Lenfant, Claude ^j   Carter, Barry L ^k   Cohen, Jerome D ^l   Colman, Pamela J ^m   Cziraky, Mark J ⁿ   Davis, John J ^o   Ferdinand, Keith Copelin ^p   Gifford, Ray W ^q   Glick, Michael ^r   Havas, Stephen ^s   Hostetter, Thomas H ^t   Kirby, Lynn ^u   Kolasa, Kathryn M ^v   Linas, Stuart ^w   Manger, William M ^x   Marshall, Edwin C ^y   Merchant, Jay ^z   Miller, Nancy Houston ^aa   Moser, Marvin ^ab   Nickey, William A ^ac   Randall, Otelio S ^ad   Reed, James W ^ae   Shaughnessy, Lee ^af   Sheps, Sheldon G ^ag   Snyder, David B ^ah   Sowers, James R ^ai   Steiner, Leonard M ^aj   Stout, Ronald ^ak   Strickland, Rita D ^al   Vallbona, Carlos ^am   Weiss, Howard S ^an   Whisnant, Jack P ^ao   Wilson, Gerald J ^ap   Winston, Mary ^aq   Karimbakas, Joanne ^ar   more..

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^k UNIVERSITY OF IOWA   (United States)

^l SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m American Society of Podiatry Medicine   (United States)

ⁿ HEALTHCORE INC   (United States)

^o American Academy of Physician Assistants   (United States)

^p Heartbeats Life Center   (United States)

^q LERNER RESEARCH INSTITUTE   (United States)

^r RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

^s UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^t NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^u Biostatistics   (United States)

^v EAST CAROLINA UNIVERSITY   (United States)

^w UNIVERSITY OF COLORADO   (United States)

^x NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^y INDIANA UNIVERSITY   (United States)

^z CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

^aa STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ab YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ac PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^ad HOWARD UNIVERSITY HOSPITAL   (United States)

^ae MOREHOUSE SCHOOL OF MEDICINE   (United States)

^af National Stroke Association   (United States)

^ag MAYO CLINIC   (United States)

^ah HEALTH RESOURCES AND SERVICES ADMINISTRATION   (United States)

^ai SUNY DOWNSTATE MEDICAL CENTER   (United States)

^aj Eye Group   (United States)

^ak PROCTER AND GAMBLE COMPANY   (United States)

^al NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^am BAYLOR COLLEGE OF MEDICINE   (United States)

^an GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^ao MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^ap Citizens for Public Action on High Blood Pressure and Cholesterol   (United States)

^aq AMERICAN HEART ASSOCIATION   (United States)

^ar AMERICAN INSTITUTES FOR RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR; DIURETIC AGENT; VASODILATOR AGENT;

AGE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; EMPATHY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE; MOTIVATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING; ALGORITHM; ARTICLE; BLOOD PRESSURE; DIAGNOSTIC TEST; DRUG ANTAGONISM; MONITOR; RISK REDUCTION;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ALGORITHMS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIAGNOSTIC TESTS, ROUTINE; DIURETICS; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN; RISK FACTORS; RISK REDUCTION BEHAVIOR; VASODILATOR AGENTS;

EID: 0038460302     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.19.2560     Document Type: Review

References (81)

1. Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446. Pr
2. US Department of Health and Human Services, National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program. Available at: http://www.nhlbi.nih.gov/about/nhbpep/index.htm. Accessed March 5, 2003.
3. Sheps SG, Roccella EJ. Reflections on The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Curr Hypertens Rep. 1999;1:342-345. Pr
4. Roccella EJ, Kaplan NM. Interpretation and evaluation of clinical guidelines. In: Izzo JL Jr, Black HR, eds. Hypertension Primer. Dallas, Tex: American Heart Association; 2003:126-127. Pr
5. Last JM, Abramson JH, eds. A Dictionary of Epidemiology. 3rd ed. New York, NY: Oxford University Press; 1995.
6. Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in The Framingham Heart Study. Lancet 2001;358:1682-1686. F
7. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003-1010. F
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet. 2002;360:1903-1913. M
9. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA. 2002;288:1882-1888. Pr
10. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet. 2000;356:1955-1964. M
11. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35:539-543. X
12. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 summary. Advance Data. 2002;328:1-32. Pr
13. Izzo JL Jr, Levy D, Black HR. Clinical Advisory Statement: importance of systolic blood pressure in older Americans. Hypertension. 2000;35:1021-1024. Pr
14. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404. Ra
15. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and elderly blood pressure control in the CONVINCE trial. Hypertension. 2001;37:12-18. Ra
16. World Hypertension League. Measuring your blood pressure. Available at: http://www.mco.edu/org/whl/bloodpre.html. Accessed April 1, 2003.
17. Pickering T. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens. 1996;9:1-11. Pr
18. Verdecchia P. Prognostic value of ambulatory blood pressure. Hypertension. 2000;35:844-851. Pr
19. American Heart Association. Home monitoring of high blood pressure. Available at: http://www.americanheart.org/presenter.jhtml?idenfifier=576. Accessed April 1, 2003.
20. 2 by MDRD (±SUN and SAIb). Available at: http://www.hdcn.com/calcf/gfr.htm. Accessed April 1, 2003.
21. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(suppl 1):S80-S82. Pr
22. National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease: Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39(suppl 2): S1-S246. Pr
23. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidencein overweight people with high-normal blood pressure. Arch Intern Med. 1997;157:657-667. Ra
24. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35:544-549. F
25. Sacks FM, Svetkey LP, Vollmer WM, et al, for the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-10. Ra
26. Vollmer WM, Sacks FM, Ard J, et al. Effects of diet and sodium intake on blood pressure. Ann Intern Med. 2001;135:1019-1028. Ra
27. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. Hypertension. 2000;35:858-863. Pr
28. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure. Hypertension. 2000;35:838-843. M
29. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure. Ann Intern Med. 2002;136:493-503. M
30. Xin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure. Hypertension. 2001;38:1112-1117. M
31. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082. Ra
32. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE). Lancet 2002;359:995-1003. Ra
33. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-convering enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981-2997. Ra
34. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153. Ra
35. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041. Ra
36. Wing LMH, Reid CM, Ryan P, et al, for Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592. Ra
37. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA. 1997;277:739-745. M
38. Physicians' Desk Reference. 57th ed. Oradell, NJ: Medical Economics; 2003.
39. Psaty BM, Manolio TA, Smith NL, et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults. Arch Intern Med. 2002;162:2325-2332. X
40. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol. 2001;38:2101-2113. Pr
41. Tepper D. Frontiers in congestive heart failure: effect of metoprolol CR/XL in chronic heart failure. Congest Heart Fail 1999;5:184-185. Ra
42. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658. Ra
43. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773. Ra
44. The SOLVD Investigators. Effect of enalapol on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302. Ra
45. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828. Ra
46. Kober L, Torp-Pedersen C, Carlsen JE, et al, for Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-1676. Ra
47. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675. Ra
48. Pitt B, Zannad F, Remme WJ, et al, for Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717. Ra
49. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2002;40:1366-1374. Pr
50. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA. 1982;247:1707-1714. Ra
51. Hager WD, Davis BR, Riba A, et al, for the Survival and Ventricular Enlargement (SAVE) Investigators. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: the SAVE Study Experience. Am Heart J. 1998;135:406-413. Ra
52. The Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390. Ra
53. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. Ra
54. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720. Ra
55. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462. Ra
56. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Iosartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869. Ra
57. Lewis EJ, Hunsicker LG, Clarke WR, et al. Reno-protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860. Ra
58. The GISEN (Gruppo Italiano di Studi Epidemiologic in Nefrologia) Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinudc, non-diabetic nephropathy. Lancet 1997;349:1857-1863. Ra
59. Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:1636-1643. Ra
60. Bakris GL, Weir MR, for the Study of Hypertension and Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes. J Clin Hypertens (Greenwich). 2003;5:201-210. Ra
61. Antithrombotic Trialist Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. M
62. Pfeffer MA, Braunwald E, Moye LA, et al, for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677. Ra
63. Lindholm LH, Ibsen M, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet. 2002;359:1004-1010. Ra
64. Bakris GL, Williams M, Dworkin L, et al, for National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes. Am J Kidney Dis. 2000;36:646-661. Pr
65. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Arch Intern Med. 2000;160:685-693. M
66. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421. Pr
67. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of Iosartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventdcular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491-1498. Ra
68. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486. X
69. Staessen JA, Wang J. Blood-pressure lowering for the secondary prevention of stroke [commentary]. Lancet. 2001;358:1026-1027.
70. Di Bari M, Pahor M, Franse LV, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial. Am J Epidemiol. 2001;153:72-78. Ra
71. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321-333. Ra
72. National High Blood Pressure Education Program. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183: S1-S22. Pr
73. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 Task Force Report on high blood pressure in children and adolescents. Pediatrics. 1996;98:649-658. Pr
74. Barlow SE, Dietz WH. Obesity evaluation and treatment: expert committee recommendations. Pediatrics. 1998;102:E29. Pr
75. Barrier PA, Li JT, Jensen NM. Two words to improve physician-patient communication: what else? Mayo Clin Proc. 2003;78:211-214. Pr
76. Betancourt JR, Carrillo JE, Green AR. Hypertension in multicultural and minority populations. Curr Hypertens Rep. 1999;1:482-488.
77. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825-834.
78. Balas EA, Weingarten S, Garb CT, et al. Improving preventive care by prompting physicians. Arch Intern Med. 2000;160:301-308. C
79. Boulware LE, Daumit GL, Frick KD, et al. An evidence-based review of patient-centered behavioral interventions for hypertension. Am J Prev Med. 2001;21:221-232. Pr, M
80. Hill MN, Miller NH. Compliance enhancement: a call for multidisciplinary team approaches. Circulation. 1996;93:4-6.
81. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727. X